Mucosal immunization with experimental feline immunodeficiency virus (FIV) vaccines induces both antibody and T cell responses but does not protect against rectal FIV challenge

Vaccine

Volumn 18, Issue 28, 2000, Pages 3254-3265

  Finerty, Susan ^a   Stokes, Christopher R ^a   Gruffydd Jones, Timothy J ^a   Hillman, Timothy J ^a   Reeves, Nicki A ^a   Whiting, Christine V ^a   Schaaper, Wim M M ^b   Dalsgaard, Kristian ^c   Harbour, David A ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b WAGENINGEN UNIVERSITY   (Netherlands)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Feline immunodeficiency virus; Mucosal immunization; Palmitoyl thioester

Indexed keywords

VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CAT; CONTROLLED STUDY; FELINE IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNIZATION; MUCOSA; NONHUMAN; PRIORITY JOURNAL; VIRUS ENVELOPE; VIRUS TRANSMISSION;

EID: 0034257003     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00131-6     Document Type: Article

References (36)

1. Pedersen N.C., Ho E.W., Brown M.L., Yamamoto J.K. Isolation of a T-lymphotropic lentivirus from domestic cats with an immunodeficiency-like syndrome. Science. 235:1987;790-793.
2. Willett B.J., Flynn J.N., Hosie M.J. FIV infection of the domestic cat: an animal model for AIDS. Immunol. Today. 18:1997;182-189.
3. Bishop S.A., Stokes C.R., Gruffydd-Jones T.J., Whiting C.V., Harbour D.A. Vaginal and rectal infection of cats with feline immunodeficiency virus. Veterinary Microbiology. 51:1996;217-227.
4. Burkhard M.J., Obert L.A., O'Neil L.L., Diehl L.J., Hoover E.A. Mucosal transmission of cell-associated and cell-free feline immunodeficiency virus. AIDS Res. Hum. Retrovir. 13:1997;347-355.
5. Bendinelli M., Pistello M., Lombardi S., et al. Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen. Clin. Microbiol. Rev. 8:1995;87-112.
6. Elyar J.S., Tellier M.C., Soos J.M., Yamamoto J.K. Perspectives on FIV vaccine development. Vaccine. 15:1997;1437-1444.
7. Hosie M.J., Flynn J.N., Rigby M.A., et al. DNA vaccination affords significant protection against feline immunodeficiency virus infection without inducing detectable antiviral antibodies. J. Virol. 72:1998;7310-7319.
8. Yamamoto J.K., Okuda T., Ackley C.D., et al. Experimental vaccine protection against feline immunodeficiency virus. AIDS Res. Hum. Retrovir. 7:1991;911-922.
9. Hosie M.J., Osborne R., Yamamoto J.K., Neil J.C., Jarrett O. Protection against homologous but not heterologous challenge induced by inactivated feline immunodeficiency virus vaccines. J. Virol. 69:1995;1253-1255.
10. Bishop S.A., Stokes C.R., Gruffydd-Jones T.J., et al. Vaccination with fixed feline immunodeficiency virus (FIV) infected cells: protection, breakthrough and specificity of response. Vaccine. 14:1996;1243-1250.
11. Gallichan W.S., Rosenthal K.L. Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization. JID. 177:1998;1155-1161.
12. Belyakov I.M., Derby M.A., Ahlers J.D., et al. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc. Natl. Acad. Sci. USA. 95:1998;1709-1714.
13. Lehner T., Brookes R., Panagiotidi C., et al. T- and B-cell functions and epitope expression in nonhuman primates immunized with simian immunodeficiency virus antigen by the rectal route. Proc. Natl. Acad. Sci. USA. 90:1993;8638-8642.
14. Imaoka K., Miller C.J., Kubota M., et al. Nasal immunization of nonhuman primates with simian immunodeficiency virus p55+gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues. J. Immunol. 161:1998;5952-5958.
15. Miller C.J., McChesney M.B., Lu X., et al. Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239. J. Virol. 71:1997;1911-1921.
16. Lehner T., Wang Y.F., Cranage M., et al. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nature Medicine. 2:1996;767-775.
17. Lombardi S., Garzelli C., La Rosa C., et al. Identification of a linear neutralization site within the third variable region of feline immunodeficiency virus envelope. J. Virol. 67:1993;4742-4749.
18. Flynn J.N., Cannon C.A., Rigby M.A., Neil J.C., Jarrett O. Induction of feline immunodeficiency virus-specific cell-mediated and humoral immune responses following immunization with a multiple antigenic peptide from the envelope V3 domain. Immunology. 85:1995;171-175.
19. Beekman N.J.C.M., Schaaper W.M.M., Tesser G.I., et al. Synthetic peptide vaccines: palmitoylation of peptide antigens by a thioester bond increases immunogenicity. Journal of Peptide Research. 50:1997;357-364.
20. Cox J.C., Coulter A.R. Adjuvants - a classification and review of their modes of action. Vaccine. 15:1997;248-256.
21. Williams N.A., Hirst T.R., Nashar T.O. Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic. Immunol. Today. 20:1999;95-101.
22. Fields C.G., Lloyd D.H., MacDonald R.L., Otteson K.M., Noble R.L. HBTU activation for automated Fmoc solid phase peptide synthesis. Peptide Research. 4:1991;95-101.
23. Harley R., Gruffydd-Jones T.J., Day M.J. Determination of salivary and serum immunoglobulin concentrations in the cat. Vet. Immunol. Immunopathol. 65:1998;99-112.
24. Flynn J.N., Cannon C.A., Beatty J.A., et al. Induction of feline immunodeficiency virus-specific cytotoxic T cells in vivo with carrier-free synthetic peptide. J. Virol. 68:1994;5835-5844.
25. Marinaro M., Staats H.F., Hiroi T., et al. Mucosal adjuvant effect of cholera-toxin in mice results from induction of T-helper-2 (TH2) cells and IL-4. J. Immunol. 155:1995;4621-4629.
26. Clerici M., Shearer G.M. The Th1-Th2 hypothesis of HIV infection: new insights. Immunol. Today. 15:1994;575-581.
27. Staats H.F., Montgomery S.P., Palker T.J. Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses. AIDS Res. Hum. Retrovir. 13:1997;945-952.
28. Lombardi S., Garzelli C., Pistello M., et al. A neutralizing antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity. J. Virol. 68:1994;8374-8379.
29. Matteucci D., Pistello M., Mazzetti P., et al. Vaccination protects against in vivo-grown feline immunodeficiency virus even in the absence of detectable neutralizing antibodies. J. Virol. 70:1996;617-622.
30. Hosie M.J., Flynn J.N. Feline immunodeficiency virus vaccination: characterization of the immune correlates of protection. J. Virol. 70:1996;7561-7568.
31. Flynn J.N., Cannon C.A., Sloan D., Neil J.C., Jarrett O. Suppression of feline immunodeficiency virus replication in vitro by a soluble factor secreted by CD8+ T lymphocytes. Immunology. 96:1999;220-229.
32. Kent S.J., Hu S.L., Corey L., Morton W.R., Greenberg P.D. Detection of simian immunodeficiency virus (SIV)-specific CD8+ T cells in macaques protected from SIV challenge by prior SIV subunit vaccination. J. Virol. 70:1996;4941-4947.
33. Heeney J.L., Teeuwsen V.J.P., Van Gils M., et al. β-Chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques. Proc. Natl. Acad. Sci. USA. 95:1998;10803-10838.
34. Lehner T., Wang Y.F., Ping L., et al. The effect of route of immunization on mucosal immunity and protection. JID. 179:1999;S489-S492.
35. Murphey-Corb M., Wilson L.A., Trichel A.M., et al. Selective induction of protective MHC class I-restricted CTL in the intestinal lamina propria of rhesus monkeys by transient SIV infection of the colonic mucosa. J. Immunol. 162:1999;540-549.
36. Stokes C.R., Finerty S., Gruffydd-Jones T.J., Sturgess C.P., Harbour D.A. Mucosal infection and vaccination against feline immunodeficiency virus. Journal of Biotechnology. 73:1999;213-221.